A Phase II Study of Sequential Carfilzomib, Clarithromycin, Lenalidomide, and Dexamethasone (Car-BiRD) Therapy for Subjects with Newly Diagnosed Multiple Myeloma

Study Status

Open to Enrollment

Study Description

The purpose of this study s to determine the safety and effectiveness of the carfilzomib and dexamethasone drug combination given prior to the BiRD regimen (Biaxin, Revlimid and Dexamethasone) in patients newly diagnosed with multiple myeloma.

Although new anti-myeloma therapies have been developed, patients are still not cured of their disease. In a previous research study conducted at Weill Cornell Medical College, newly diagnosed multiple myeloma patients responded well to the BiRD regimen.

The new investigational drug called carfilzomib is a proteasome inhibitor. Proteasomes are found inside all cells. Blocking the action of proteasomes causes cells to die, and cancer cells are more susceptible to this effect than normal cells. The investigators hope that giving carfilzomib and dexamethasone before BIRD will lead to improvement in myeloma reduction.

Treatment Plan:

All patients will begin treatment with Carfilzomib + Dexamethasone. Carfilzomib will be given intravenous at a dose of 45mg/m2 on days 1, 2, 8, 9, 15, 16 for each 28-day cycle. Dexamethasone (Decadron®) will be given orally at a dose of 20 mg on days 1, 2, 8, 9, 15, 16, 22 and 23 for each 28-day cycle.

At the maximum disease response on Carfilzomib + Dexamethasone treatment, patients will then transition to BiRD therapy. BiRD is: Clarithromycin (Biaxin®) orally at a dose of 500 mg twice a day, Dexamethasone (Decadron®) orally at a dose of 40 mg on days 1, 8, 15 and 22, and Lenalidomide (Revlimid®) orally at a dose of 25 mg/day days 1-21 out of a 28-day cycle.

At the maximum disease response on BiRD, patients may then choose either to proceed to autologous stem cell transplant or Lenalidomide (Revlimid®) which will be given as a maintenance medication at a dose of 10 mg/day days 1-21 out of a 28-day cycle. Patients can continue on Lenalidomide maintenance for a maximum of 24 cycles (approximately 2 years).

If there is progression of myeloma at any time, the study medications will end and alternative treatment will be offered.

Follow the Myeloma Center online:

Website: http://myelomacenter.org

Blog: http://myelomacenterblog.com

Facebook: Click here to visit the Myloma Facebook Page

Disease Status and/or Stage

Newly Diagnosed Multiple Myeloma; No Previous Treatment

Sponsor

Weill Cornell Medical College

Key Eligibility

  • Men and women age 18 and older
  • Multiple Myeloma
  • No previous treatment
  • Detailed eligibility reviewed when you contact the study team

Principal Investigator

Tomer Mark, MD

Contact


Healthy Volunteers

healthy_volunteers.jpg

As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Erica Bersin
Tel: (646) 962-8232
erb3001@med.cornell.edu

Top of page